Megalotect Cp (Human Cytomegalovirus Immunoglobulin)

Megalotect Cp, an immunoglobulin targeting human cytomegalovirus, is indicated for the following clinical situations:

• Prevention of cytomegalovirus infection in transplant recipients: reduces the incidence of CMV disease after solid‑organ transplantation.
• Treatment of CMV disease in immunocompromised patients: aids viral clearance and alleviates clinical symptoms.
• Prophylaxis in high‑risk hematopoietic stem cell transplantation: provides passive immunity during the engraftment phase.

• Human Cytomegalovirus Immunoglobulin supplies a concentrated pool of polyclonal antibodies derived from screened donors. These antibodies bind to CMV viral particles and glycoproteins, neutralizing the virus and preventing cell entry. The immune complexes are then cleared by phagocytes, and antibody‑dependent cellular cytotoxicity contributes to viral elimination, thereby conferring passive immunity to the recipient. The administered IgG also modulates the host immune response, enhancing opsonization and complement activation against CMV.

Megalotect Cp may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Fever: transient elevation of body temperature during or shortly after infusion.
• Chills: shaking sensations commonly reported with intravenous immunoglobulin.
• Headache: mild to moderate headache occurring during infusion.
• Nausea: occasional nausea or upset stomach.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical intervention.
• Thromboembolic events: risk of clot formation, especially in patients with pre‑existing risk factors.
• Renal dysfunction: acute kidney injury may occur, particularly with rapid infusion.
• Aseptic meningitis: rare inflammatory response of the meninges without infection.

Prior to initiating Megalotect Cp therapy, clinicians should consider several precautionary measures to ensure patient safety.

• Renal function: monitor renal parameters in patients with pre‑existing kidney disease.
• Thrombotic risk: assess history of thrombosis before infusion and adjust infusion rate if needed.
• Allergy: verify no known hypersensitivity to human immunoglobulins or IgA deficiency.
• Pregnancy: use only if potential benefit justifies potential risk, as data are limited.
• Infusion rate: administer slowly and monitor vital signs throughout the infusion.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Megalotect Cp can interact with other medicines; awareness of major and moderate interactions helps optimize therapy.

Major Interactions (Avoid)

• Live vaccines: concurrent use may reduce vaccine efficacy or increase risk of infection.
• High‑dose immunosuppressants: may diminish the therapeutic effect of the immunoglobulin.
• Anticoagulants: increased risk of thrombotic complications when combined.

Moderate Interactions (Monitor Closely)

• Renally cleared drugs (e.g., aminoglycosides): monitor renal function during combined therapy.
• Other intravenous immunoglobulins: risk of volume overload and increased adverse events.